Show simple item record

dc.contributor.authorKivata, MW
dc.contributor.authorMbuchi, M
dc.contributor.authorEyase, FL
dc.contributor.authorBulimo, WD
dc.contributor.authorKyanya, CK
dc.contributor.authorOundo, V
dc.contributor.authorMuriithi, SW
dc.contributor.authorAndagalu, B
dc.contributor.authorMbinda, WM
dc.contributor.authorSoge, OO
dc.contributor.authorMcClelland, RS
dc.contributor.authorSang, W
dc.contributor.authorMancuso, JD
dc.date.accessioned2019-06-24T08:27:37Z
dc.date.available2019-06-24T08:27:37Z
dc.date.issued2019-04-08
dc.identifier.citationBMC Microbiol. 2019 Apr 8;19(1):76en_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pubmed/30961546
dc.identifier.urihttp://erepository.uonbi.ac.ke/handle/11295/106480
dc.description.abstractPhenotypic fluoroquinolone resistance was first reported in Western Kenya in 2009 and later in Coastal Kenya and Nairobi. Until recently gonococcal fluoroquinolone resistance mechanisms in Kenya had not been elucidated. The aim of this paper is to analyze mutations in both gyrA and parC responsible for elevated fluoroquinolone Minimum Inhibitory Concentrations (MICs) in Neisseria gonorrhoeae (GC) isolated from heterosexual individuals from different locations in Kenya between 2013 and 2017. METHODS: Antimicrobial Susceptibility Tests were done on 84 GC in an ongoing Sexually Transmitted Infections (STI) surveillance program. Of the 84 isolates, 22 resistant to two or more classes of antimicrobials were chosen for analysis. Antimicrobial susceptibility tests were done using E-test (BioMerieux) and the results were interpreted with reference to European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards. The isolates were sub-cultured, and whole genomes were sequenced using Illumina platform. Reads were assembled de novo using Velvet, and mutations in the GC Quinolone Resistant Determining Regions identified using Bioedit sequence alignment editor. Single Nucleotide Polymorphism based phylogeny was inferred using RaxML. RESULTS: Double GyrA amino acid substitutions; S91F and D95G/D95A were identified in 20 isolates. Of these 20 isolates, 14 had an additional E91G ParC substitution and significantly higher ciprofloxacin MICs (p = 0.0044*). On the contrary, norfloxacin MICs of isolates expressing both GyrA and ParC QRDR amino acid changes were not significantly high (p = 0.82) compared to MICs of isolates expressing GyrA substitutions alone. No single GyrA substitution was found in the analyzed isolates, and no isolate contained a ParC substitution without the simultaneous presence of double GyrA substitutions. Maximum likelihood tree clustered the 22 isolates into 6 distinct clades. CONCLUSION: Simultaneous presence of amino acid substitutions in ParC and GyrA has been reported to increase gonococcal fluoroquinolone resistance from different regions in the world. Our findings indicate that GyrA S91F, D95G/D95A and ParC E91G amino acid substitutions mediate high fluoroquinolone resistance in the analyzed Kenyan GC.en_US
dc.language.isoenen_US
dc.publisherBMCen_US
dc.subjectAntimicrobial resistance (AMR)en_US
dc.subjectFluoroquinolonesen_US
dc.subjectMutationen_US
dc.subjectNeisseria gonorrhoeaeen_US
dc.subjectQuinolone resistant determining regions (QRDRen_US
dc.titlegyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya.en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record